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40% of that population. This raises a serious question about
proceeding to transplantation in the first year of the disease, as four
centers have advised on the basis of their perception that DCM
had such a poor prognosis. In this published cohort, some
recovered as late as six years after onset; would 40% of the
transplanted children have recovered with normal contractility had
they not been transplanted?
Although the title of their study asserts that transplantation for
DCM will provide “improved outcomes,” that can only apply to
the first few years after cardiac transplantation, which lasts on
average 10 to 13 years. In contrast, 40% of all patients with DCM
recovered systolic function without transplantation and were still
normal eight years later. The difference between transplants and
complete recovery does not take into account the morbidity of
rejections and anti-immune treatments for the transplanted pa-
tients. If 40% of the transplanted children would have recovered,
the overall outcome would certainly not be improved.
Finally, the reliability of separating myocarditis from idiopathic
DCM is raised by their finding of no differences between the two
groups for either “heart death” or for recovery of function. This
important finding throws doubt on the criteria used to diagnose
myocarditis.
In sum, this important study by Tsirka et al. (1) provided several
important advances in our knowledge, even though the title made
promises that were unwarranted.
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We appreciate Dr. Guntheroth’s remarks regarding our retrospec-
tive observational study (1) on pediatric dilated cardiomyopathy
(DCM). His concerns appropriately point out the limitation of all
observational studies—that one can never tell what would have
happened to the treated group (in this case those who were
transplanted) had they not undergone treatment because there is
no valid comparison group. However, 75% of the patients trans-
planted in our study were on persistent inotropic support (UNOS
status 1) at the time of transplant and had failed attempts to
remove inotropic support. Data from the Pediatric Heart Trans-
plant Study (PHTS) (2) suggest that inotropic support is a risk
factor for death before transplant. Thus, we believe our patients
who underwent transplantation represented a substantially sicker
subgroup of patients within the patient population studied. How-
ever, newer heart failure therapies such as beta-blockade have been
reported to remove the survival advantage from heart transplanta-
tion in adults (3) and to decrease utilization of heart transplanta-
tion in infants and children (4). The role of heart transplantation
as therapy for pediatric DCM needs to be continually redefined as
newer heart failure therapies are applied to pediatric heart disease.
Dr. Guntheroth suggests that inclusion of patients with DCM
from metabolic disease or muscular dystrophy may be misleading
because of the uniformly fatal nature of those diseases. The
differing natural history of the Becker and Duchenne variants of
dystrophin muscular dystrophy underscores the difficulties of
lumping all metabolic cardiomyopathies and muscular dystrophies
in one common prognostic group.
We would agree with Dr. Guntheroth that the criteria used in
our study to diagnose myocarditis are not clear cut. The frequency
of viral infection in children can make it likely that any diagnosis
of a DCM can generally correlate with a “recent” viral infection.
Pathologic criteria can also be confusing given the patchy nature of
myocardial inflammation leading to false negative endomyocardial
biopsies and the presence of viral genome in myocardial samples
without evidence of inflammation (5). Thus, any clear-cut defini-
tion of myocarditis in children remains difficult.
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Cell Transplantation and Fibrin Matrix
The recent study by Christman et al. (1) reports the results of an
experimental study that evaluated a “novel approach to heart repair
that uses an injectable biopolymer scaffold to deliver cells directly
into the infarct wall.” The researchers “hypothesized that the
injection of cells in a solution that becomes a semi-rigid scaffold
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upon injection would increase cell transplant retention and survival
within the infarct, compared with the standard injection technique.”
The investigators failed to acknowledge that this theory was
presented by our group at the American Heart Association meetings
in 2001 and the American College of Cardiology meetings in 2002
and 2003. Neither do they reference our published works (both
experimental and clinical) evaluating the role of fibrin matrices as a
scaffold for cell transplantation and as an angiogenic agent. Using
transmission electron microscopy, we discovered that fibrin platform
directs the morphofunctional process of capillary formation and
accelerates neovascularization in ischemic myocardium in addition to
enhancing the viability of transplanted endothelial cells (2,3).
We documented improvement in left ventricular ejection frac-
tion, myocardial blood, and capillary density.
We avoided the possibility of higher graft rejection from using
an inbred strain and allograft transplantation, the limitation the
investigators mention, by employing autologous endothelial cells
and autologous fibrinogen for fibrin sealant preparation. Endothe-
lial cells (ECs) were cultivated from endothelium of the jugular
veins of the same sheep (3). One week before EC transplantation,
whole blood from each animal was collected, and a standard
cryoprecipitate technique was used to prepare autologous fibrino-
gen from sheep plasma. Cultured in a two-dimensional fibrin
matrix, ECs quickly formed a cobblestone monolayer that had a
density 2- to 2.5-fold higher than in controls cultivated on a
single-plane tissue culture surface (4). We also found that, cultured in
a three-dimensional fibrin matrix, ECs formed true capillaries, while
other vascular cells trapped in this matrix underwent apoptosis.
In our next investigation, we found that a fibrin-based sealant
becomes vascularized when placed between two ischemic tissues and
that aprotinin, added to fibrinogen, considerably increased the process
of neovascularization (5). Fibrin-based sealant proved capable of
delivering plasma proteins necessary to perform the functions of an
extracellular matrix, anchoring ECs to the vessel wall (6).
Finally, we demonstrated that fibrin-based sealant accelerates
angiogenesis in patients with peripheral artery disease (7).
We thank Christman et al. (1) for their interesting contribution
on this subject and applaud the renewed interest in this worthy line
of inquiry. With further preclinical and clinical investigation of the
safety and efficacy of this technique, we believe that fibrin matrix
as a scaffold for cell therapy, and the angiogenic potential of fibrin
compositions, show promise for the treatment of heart disease.
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Our report (1) is the first study to demonstrate the beneficial effects
of intramyocardial injection of a biopolymer alone in inducing
angiogenesis and reducing infarct expansion. Furthermore, we
have demonstrated that compositions of fibrin glue injected into
ischemic myocardium prevent the negative remodeling associated
with a myocardial infarction (MI) (2). These dramatic results were
shown both for fibrin glue alone, and in material compositions of
fibrin glue combined with transplanted, healthy myoblasts. Addi-
tionally, our report demonstrated that a fibrin glue scaffold
increased the survival of contractile-type muscle cells, more spe-
cifically myoblasts, transplanted into myocardial tissue.
One hypothesis we tested was that an acellular intramyocardial
injection of a biopolymer could prevent infarct expansion and
prevent the continued worsening in left ventricular (LV) function
following an MI. Dr. Chekanov and colleagues provide corrobo-
rative data regarding the utility of biopolymers. However, the
emphasis of the experiments cited by Chekanov and colleagues had
different objectives. In their earlier citations (3), Chekanov et al.
used an autologous biologic glue containing fibrinogen epicardially
to enhance the healing process of cardiomyoplasty. The autologous
biologic glue was used “as an interlayer between the stimulated
latissimus dorsi muscle and the myocardium to improve adhesion
formation and cardiomyoplasty results.”
Another hypothesis we tested was that fibrin glue matrix, in
combination with myoblasts, enhances LV function. This test was
specifically designed around use of a contractile type of cells.
Accordingly, our work demonstrates an advancement by showing
pronounced beneficial effects of fibrin glue-assisted myoblast
transplantation into ischemic myocardium. Chekanov et al. (4) did
report results of an experimental protocol to observe the effects of
transplanting endothelial cells (ECs) in a fibrin matrix into
ischemic myocardium. However, the experimental design was
principally based upon a hypothesis of neovascularization and
consisted of the following three groups: 1) ECs and fibrin matrix,
2) saline with denatured cells, and 3) a control group. The
investigators did not include a fibrin matrix group alone or healthy
ECs alone. Therefore, they did not test whether a biopolymer
alone injected intramyocardially could produce angiogenesis or
prevent the negative remodeling associated with an MI.
Additionally, without observing the effects of a healthy EC
group without fibrin glue, the researchers could not determine the
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